Neuraxpharm reinforces its European CNS leadership with acquisition

Spain-based specialty drugmaker Neuraxpharm Group, focused on the treatment of central nervous system disorders (CNS), has acquired Farmax, a CNS specialty pharmaceutical company, from Czech contract manufacturer SVUS Pharma. The financial terms of the transaction were not disclosed.

Farmax, located in Hradec Králové, Czech Republic, was the commercial division of SVUS Pharma, and has a strong distribution presence in the Czech Republic, Slovakia as well as a small presence in Hungary. Farmax is a leader in sales and marketing both branded and non-branded generics pharmaceuticals for CNS disorders such as Zolpinox (zolpidem). Zolpidem is the active ingredient of Sanofi’s (Euronext: SAN) blockbuster drug Ambien. Farmax also commercializes well-known OTC nutraceuticals such as Preventan and Maxicor.

Farmax has been renamed Neuraxpharm Bohemia and will commercialize its products under the Neuraxpharm brand. Leveraging its proprietary sales force in the Czech Republic, Slovakia and Hungary, Neuraxpharm Bohemia plans to quickly offer new and differentiated products to local patients and healthcare providers based on the group’s broad CNS portfolio.